B-cell acute lymphoblastic leukemia (B-ALL) is often associated with chromosomal translocations leading to the deregulation of proto-oncogenes. MicroRNAs can also be affected by chromosomal alterations and thus contribute to carcinogenesis. The microRNA, miR-125b-1, is overexpressed in B-ALL cases with the t(11;14)(q24;q32) translocation; therefore, we sought to determine the role of this microRNA in B-cell fate. We used murine pre-BI cells alongside murine and human leukemic B-cell lines to show that miR-125b expression enhances proliferation by targeting B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ ARID3a, an activator of immunoglobulin heavy-chain transcription. Accordingly, this target gene was downregulated in B-ALL patients with the t(11;14)(q24;q32) translocation. Repression of Bright/ARID3a blocked differentiation and conferred a survival advantage to Ba/F3 cells under interleukin-3 starvation. In addition, overexpression of miR-125b protected pre-BI and leukemic B-cell lines from apoptosis by blockade of caspase activation by a mechanism that was independent of p53 and BAK1. In summary, miR-125b can act as an oncogene in B-ALL by targeting ARID3a and mediating its repression, thus leading to a blockage in differentiation, increased proliferation and inhibition of apoptosis.
INTRODUCTION
B-cell acute lymphoblastic leukemia (B-ALL) is characterized by a population of immature lymphoblastic cells with unlimited proliferative potential and arises from progenitor B-cells at the pro/pre-B-cell stage. Two distinct events occur during malignant transformation: (1) a blockage of differentiation at the pre-B-cell stage and (2) an acquisition of unlimited proliferative potential. 1 The primary events leading to malignant transformation are often structural mutations such as deletions, amplifications or translocations that result in either the generation of fusion genes or the deregulation of proto-oncogenes. As well as classical protein-coding genes, microRNAs are often upregulated or downregulated by such chromosomal translocations as they are frequently found at fragile sites within the genome. 2, 3 miR-125b, the homolog of the Caenorhabditis elegans lin-4 gene, is one of the microRNAs most frequently associated with cancer. [4] [5] [6] [7] [8] In humans, there are two miR-125b gene loci: miR125b-1 on chromosome 11q23 and miR-125b-2 on chromosome 21q21; these are differentially expressed depending on the tissue type. Although their pri-microRNAs have slightly different sequences, mature miR-125b-1 and miR-125b-2 are identical and both are reported to be overexpressed in certain solid tumors 4 and hematological malignancies. 5, 6 In hematological malignancies, miR-125b-1 has been shown to be overexpressed in some cases of acute myeloid leukemia and myelodysplastic syndrome secondary to a t(2;11)(p21;q23) translocation. In these cases, miR-125b-1 seems to contribute to oncogenesis by blocking myeloid differentiation. 5 miR-125b is also involved in B-cell malignancies such as B-ALLs containing the ETV6/RUNX1 translocation, although in these cells miR-125b-2 overexpression is independent of the ETV6/RUNX1 fusion protein and is thought to confer a survival advantage. 7 Three other studies have reported B-ALL cases with an isolated chromosomal aberration whereby miR-125b-1 is found inserted into the immunoglobulin heavychain locus, resulting in its upregulation. [8] [9] [10] Given these cases where miR-125b is involved in B-ALL and the fact that miR-125b blocks differentiation in myeloid progenitor cells, 5 we sought to determine the effects of miR-125b overexpression in B-cell progenitors and in B-ALL.
MATERIALS AND METHODS

Patient samples
Samples of complimentary DNA from B-ALL patients with and without the chromosomal translocation t(11;14)(q24;q32) were provided by Dr Florence N'Guyen-Khac. Clinical details are already published, as described in Chapiro et al. 9 Cell culture
The Phoenix retrovirus producer line (Orbigen, Inc., San Diego, CA, USA) was cultured in Dulbecco's Modified Eagle's Medium-high glucose (Life Technologies, Foster City, CA, USA), 10% fetal calf serum (FCS) ( Carlsbad, CA, USA). Murine OP9 bone marrow stromal cells were cultured in minimum essential medium-a (Life Technologies), 20% FCS. Murine wild-type pre-BI cells were isolated from C57BL/6 mouse bone marrow as being B220
þ /cKIT þ /Igk À and were cultured on a monolayer of irradiated OP9 stromal cells in Iscove's Modified Dulbecco's Medium (Life Technologies), supplemented with 20% FCS, 100 units/ml murine interleukin (IL)-7 (Peprotech, RockyHill, CT, USA), 0.05 mM b-Mercaptoethanol (SigmaAldrich, St Louis, MO, USA) and 2 mM L-Glutamine (Invitrogen). Every 3 days, pre-BI cells were harvested and propagated on fresh OP9 stromal cells. Murine B-ALL cell lines 38B9 and 18-81, and human Nalm6 pre-Bcells were cultured in RPMI (Life Technologies), 10% FCS, 2 mM L-Glutamine and 1 mM Sodium-Pyruvate (Invitrogen). This was supplemented with either 0.05 mM b-Mercaptoethanol or 100 units/ml murine IL-3 (Peprotech) to culture the murine B-ALL cell lines 70Z/3 and BaF/3, respectively. All cells were cultured in the presence of penicillin (100 U/ml) and streptomycin (100 mg/ml) at 37 1C in a 5% CO 2 atmosphere.
Antibodies and cell sorting
For fluorescence-activated cell sorting (FACS) and flow cytometry analyses, we used the following antibodies: phycoerythrin/Cy5.5-conjugated antimouse B220 (Southern Biotech, Birmingham, AL, USA), fluorescein isothiocyanate-and phycoerythrin-conjugated anti-mouse Igk (BD Pharmingen, San Diego, CA, USA), phycoerythrin-conjugated anti-mouse c-Kit and biotin-conjugated anti-mouse BP1 (both obtained from eBioscience, Inc., San Diego, CA, USA) and allophycocyanin-conjugated streptavidin (BD Pharmingen). After staining, flow cytometry was performed using a FACSCalibur or FACScan (both obtained from BD Biosciences, San Jose, CA, USA); data were analyzed with FlowJo Software (Treestar, Ashland, OR, USA). Cell sorting was performed using a FACSAria II (BD Biosciences).
Retroviral transduction
Retroviral supernatants were produced by the Phoenix retrovirus producer line (Orbigen) using the Lipofectamine 2000 (Invitrogen) reagent for transfection, according to the manufacturers' instructions. Then, cells were treated with 10 mM Sodium Butyrate (Millipore, Billeria, MA, USA) and washed with phosphate-buffered saline before Pre-BI cell medium was added. Viral supernatants were harvested after 24 h of incubation at 32 1C and filtered through a 0.45-mm filter. Pre-BI cells, cultured on OP9 stromal cells in the presence of IL-7, were transduced on the third day after isolation from the bone marrow. Retroviral supernatant was diluted 1:3, supplemented with polybrene to a final concentration of 3 mg/ml (Sigma-Aldrich), then transduction of pre-BI cells, 70/Z3 and BaF/3 cells was performed by spin infection at 3500 r.p.m., 32 1C for 120 min and overnight incubation at 37 1C.
IL-7 starvation assay and B-cell differentiation analysis
Cells in IL-7 were washed then plated in Iscove's Modified Dulbecco's Medium containing 5% FCS, 0.05 mM b-Mercaptoethanol and 2 mM L-Glutamine on an OP9 stroma cell layer. On day 6 cells were stained for surface BP1 and Igk light chain and analyzed by flow cytometry.
Statistical analysis
Results are shown as the mean±s.e.m. Statistical analysis was performed using the Student's t-test as provided by Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) and the null hypothesis was rejected at the 0.05 level (***Po0.0005, **Po0.005, *Po0.05).
Further information on Materials and Methods used is available in the Supplementary File. RESULTS miR-125b overexpression induces proliferation of wild-type progenitor B-cells and B-ALL cell lines To test the hypothesis that miR-125b could act as an oncogene by increasing proliferation of progenitor B-cells, we first transduced murine wild-type pre-BI cells with either an empty retroviral vector (pMIE), or a vector expressing miR-125b-1 (pMIE-125b) or mutated miR-125b-1 (pMIE-125b-mut) in the seed region. We then counted cells at different time points. Infected cells were distinguished by the expression of enhanced green fluorescent protein. After confirming miR-125b expression using reverse transcriptase quantitative PCR (Figure 1 ), transduced cells were co-cultured with OP9 cells for 6 days in the presence of IL-7. An equal number of cells from each group were taken (B70% of the B220 þ /EGFP þ population; Supplementary Figure  S1 ) and viable B-cell progenitors were counted at days 3, 8 and 11 after transduction. We found that miR-125b-overexpressing cells were constantly more abundant (Figures 2a and b) and at day 3 the number of miR-125b-transduced pre-BI cells was 40% higher than control cells. This percentage continued to increase over time, and by day 11 miR-125b-overexpressing cells were three times as abundant as control cells (Figure 2b , Po0.01), suggesting a constant growth advantage. We performed bromodeoxyuridine assays on pre-BI cells transduced with either miR-125b, miR-125b-mut or the empty vector. At days 2, 4 and 6 after transduction, bromodeoxyuridine incorporation into pre-BI cells was evaluated and we found that the rate of proliferating cells was higher in miR-125b-overexpressing cells after day 4 (Figures 2c and d Figure S2) . As expected, the percentage of cells present in S phase was higher in pMIE-miR-125b-infected cells at day 4 compared with controls (Supplementary Figure S2) . To check that the effects of miR-125b were not restricted to wild-type murine B-cell progenitors, we transfected murine (38B9, 18-81 and 70Z/3) and human (Nalm6) pre-B-cell lines with pre-miR-125b or control microRNA. We quantified miR-125b expression in these cell lines before and after transfection (Figure 3a) . At days 2, 3 and 4, we performed MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) proliferation tests and found that the miR-125b-expressing cells were more numerous in all four cell lines ( Figure 3b ). Taken together, these results suggest that overexpression of miR-125b enhances proliferation in wild-type pre-BI cells as well as in leukemic pre-B-cell lines, with these effects being more pronounced in non-leukemic contexts. Furthermore, the effects were comparable between human and murine cell lines.
miR-125b overexpression has anti-apoptotic effects independent of the p53 pathway in wild-type B-cell progenitors and in B-ALL cell lines To test whether the increased cell number induced by miR-125b is the consequence of overproliferation or decreased apoptosis, we tested the influence of miR-125b on the activation of the effector caspases 3/7 and on the loss of plasma membrane asymmetry. Wild-type and pre-BI cells transduced with miR-125b, miR-125b-mut or empty vectors were sorted for B220 þ /EGFP þ cells, then seeded on irradiated OP9 cells and cultured in cell medium Figure 1 . MicroRNA expression was determined by qRT-PCR using Taqman MicroRNA assays (Life Technologies, Foster City, CA, USA). The y axis represents relative expression levels of mature miR-125b normalized using an internal control (sno202).
miR-125b targets ARID3a in B-ALL MP Puissegur et al supplemented only with 2% FCS to induce stress conditions. Caspase activity was measured at days 2, 4 and 6 of culture, and we found that when compared with control cells at the same time point, significantly less caspase activity was found as time progressed in miR-125b-positive cells (Figure 4a ). To quantify the rate of apoptosis, we performed annexin V staining on the same pre-BI cells. From day 4 we observed a significant decrease in apoptotic cell numbers in pre-BI cells overexpressing miR-125b (annexinV þ /7-aminoactinomycin D À ) when compared with control cells at the same time point (Figure 4b ). Human and murine cell lines were also assessed for caspase activation at days 1, 2, 3 and 4 after transfection using pre-miR-125b or pre-miR-neg control microRNA (Supplementary Figure S3) . From day 2 onwards, caspase activity increased in both control and miR-125b-transfected cells but was always significantly lower in miR-125b-positive cells. Taken together, these results suggest that enforced expression of miR-125b retards activation of the apoptotic pathway and thus confers a survival advantage.
Among the predicted targets of miR-125b in the apoptotic process, one of the most interesting is p53. In humans and zebrafish, the 3 0 untranslated region of p53 mRNA has been shown to contain an active miR-125b-binding site, 11 but in mice the situation is more complex as the miR-125b-binding site of p53 is not conserved. To evaluate whether the anti-apoptotic effect of miR-125b resulted in p53 or BAK1 (a p53 effector) targeting, we measured the protein levels of p53 and BAK1 3 days after transduction in miR-125b-positive or control pro-B and B-ALL cell lines. Western blot analysis revealed that neither p53 nor BAK1 expression levels significantly changed in each case (Figure 4c , Supplementary Figure S3 ), suggesting that neither BAK1 nor p53 are targets of miR-125b in a murine pre-B cell context and that the observed anti-apoptotic effect of this microRNA is caused by p53-independent mechanisms.
Identification of an miR-125b target gene, ARID3A, which recapitulates the hyperproliferative effect of miR-125b in B-ALL cell lines To elucidate the mechanism of miR-125b-mediated growth advantage and protection from apoptosis in pre-BI cells, we tested the influence of miR-125b on the transcriptome in 70Z/3 and 18-81 cells, using methodology described previously. 12, 13 As expected, ectopic expression of miR-125b induced transcriptomic alterations in 70Z/3 and 18-81 cells 48 hours after transfection. Interestingly, using our web tool miRonTop (http:// www.microarray.fr:8080/miRonTop/index), 14 we found a specific enrichment of miR-125b-predicted targets in the set of downregulated transcripts. Whereas a moderate but significant enrichment was found with a basic complementary seed search (nucleotides 2-7 or nucleotides 2-8), a strong enrichment (460) was revealed using the validated microRNA targets database miRTaRbase (Supplementary Figure S4) . Overall, using several additional prediction tools detailed in Table 1 , an initial list of 28 putative candidates was produced. Among this list of predicted 
The mean percentage of proliferative non-transduced, pMIE, pMIE-miR-125b or pMIE-miR-125b-mut pre-BI cells at days 2, 4, 6 and 9 of culture from n ¼ 4 independent experiments are presented as means ± s.d.
miR-125b targets ARID3a in B-ALL MP Puissegur et al targets, which was established in 70Z/3 cells, a transcript encoding Arid3a was also found to be downregulated in 18-81 cells where an approximate fourfold enrichment for miR-125b-validated targets was revealed using miRTaRbase (data not shown). ARID3a is a transcription factor also known as Bright in mouse (B-cell regulator of immunoglobulin heavy-chain transcription). It is a member of the ARID (A þ T-rich interaction domain) family of proteins, which is required for both hematopoietic stem cell and B-cell lineage development. 15, 16 To test whether Arid3a was directly targeted by miR-125b, we fused the 3 0 untranslated region of Arid3a with and without three mutations in the miR-125b-binding site to the coding region of the luciferase reporter named as pSI-Arid3a-mut and pSI-Arid3a, respectively. Only cotransfection with pSI-Arid3a and a synthetic pre-miR-125b in the NIH/3T3 cells significantly decreased the luciferase activity when compared with a pre-miR-negative control, strongly suggesting that this gene is a target of miR-125b (Figure 5a, left panel) . We then confirmed the repression of the Arid3a transcript by reverse transcriptase quantitative PCR in pMIE-125-transduced pre-BI cells (Figure 5a , middle panel) and the reduction of Arid3a expression at the protein level by western blot analysis in miR-125b-expressing 70Z/3 cells (Figure 5a, right panel) . In parallel we used a specific miR-125b antisense locked nucleic acid oligonucleotide to knockdown miR-125b in human leukemic REH cells, a cell line derived from a patient with ETV6/RUNX1 leukemia that overexpresses miR-125b. After control of reduced miR-125b expression, we observed an increase both in transcription (Supplementary Figure S5 , left panel) and protein expression of ARID3a (Figure 5a , right panel). These data show definitively that ARID3a is a valid target of miR-125b.
We then investigated whether the hyperproliferative effects observed upon miR-125b expression in B-ALL cell lines might be due to the downregulation of Arid3a expression. We transduced murine B-ALL 70Z/3 cells with a retrovirus expressing small hairpin RNAs directed against Arid3a (pSh-Arid3a). After 2 days of puromycin selection, we confirmed the knockdown of Arid3a by reverse transcriptase quantitative PCR and western blot analysis (Figure 5a, right panel) . Interestingly, from day 4 we observed that (Figure 5b, left panel) . These results were validated using three different small hairpin RNAs against Arid3a to exclude the possibility of off-target effects. Moreover, we tested whether repression of Arid3a would confer independence Figure 4 . miR-125b delays apoptosis activation in pre-BI cells without alteration of p53 and BAK1 expression levels. A caspase 3/7 assay (a) and phycoerythrin-AnnexinV staining (b) were carried out on pre-BI cells transduced under the same conditions as previously described and cultured in cell medium supplemented with 2% FCS. Results correspond to three independent experiments performed in triplicate. **Po0.005, *Po0.05. (c) Effect of miR-125b expression on endogenous p53 and BAK1 levels as determined by western blot on day 3 after transduction of pre-BI cells and on day 3 after transfection of B-ALL cell lines. Abbreviation: UTR, untranslated region. The table lists the transcripts significantly downregulated following miR-125b overexpression and those predicted to be miR-125b targets using the bioinformatics tool miRonTop (http://www.microarray.fr:8080/miRonTop/index) with different prediction algorithms: (i) an exact seed search 2-7 or 1-8 seed in the 3 0 UTR; (ii) miRBase Target v5; (iii) TargetScan conserved miRTarBase v1 has been used to list the miR-125b-validated. Logarithm (base 2) of the average intensity (AveExpr) and logarithm (base 2) of the ratio of miR-125b/miR-Neg (logFC) are represented. Gene ID corresponds to the NCBI Gene IDs (http://www.ncbi.nlm.nih.gov/gene). ARID3a is repressed in B-ALL patients with the t(11;14)(q24;q32) translocation and induces expression of pluripotency-associated factors We next sought to examine whether ARID3a is downregulated in primary leukemic blasts highly expressing miR-125b. We used bone marrow samples from B-ALL patients that have been previously studied to discern whether or not they carry the recurrent IGH@ translocation, t(11;14)(q24;q32), which results in an upregulation of miR-125b. 9 Using RT-PCR we observed that ARID3a expression was lower in two patients with the translocation compared to the B-ALL controls that do not overexpress miR-125b (Figure 6a) .
Recent studies support a model in which Bright/ARID3a acts as a suppressor of lineage plasticity. 15, 17 Indeed, Bright/ARID3A inhibition causes increased developmental plasticity in mouse and human cells, 15, 17 notably by increasing the expression of pluripotency-associated factors such as Oct4, Sox2, Klf4 and Nanog. To evaluate whether repression of ARID3a can induce the transcription of these markers, we tested their expression levels using reverse transcriptase quantitative PCR in B-ALL patients with or without the t(11;14) translocation. Interestingly, we noted a significant upregulation of at least three pluripotency markers Figure 5 . miR-125b represses expression of Bright/Arid3a, which recapitulates the hyperproliferative effect of miR-125b in B-ALL cell lines. (a) NIH/3T3 cells were co-transfected with 10 nM pre-miR-Neg, pre-miR-125b and pSI-Arid3a constructs containing 3 0 untranslated region sequences with an miR-125b-binding site or a pSI-Arid3a-mut construct containing mutated seed miR-125b sequences in the 3 0 untranslated region of Arid3a (left panel). Arid3a expression was monitored by quantitative PCR on RNA from pMIE-and pMIE-miR-125b-transduced pre-B1 cells (middle panel) 2 days after transduction. Western blot analysis of Arid3a were performed on lysates extracted from pMIE-, pMIE-miR-125b-, pSh-Neg-or pSh-Arid3a-transduced 70Z/3 cells 2 days after transduction and after two supplementary days of selection by puromycin, which was necessary for small hairpin RNA expression and after knockdown of miR-125b in REH cells (right panel). . ARID3a is downregulated in B-ALL patients with an upregulation of miR-125b. Relative expression levels of ARID3a (a) and of four pluripotency-associated markers: OCT4, NANOG, SOX2 and KLF4 (b) were examined by quantitative PCR on RNA both from B-ALL patients with the recurrent IGH@ translocation, t(11;14)(q24;q32) that results in the upregulation of miR-125b and from B-ALL patients lacking this translocation, named as other B-ALL and previously described in Nixon et al.
(NANOG, SOX2 and KLF4) in patient P2 (t (11;14) þ ) (Figure 6b ). Overexpression of these markers was not observed in patient P1; however, the bone marrow sample of patient P1 was removed after the relapse causing his death. Therefore, the patient had received chemotherapy treatment that could have altered the expression of these markers. To confirm a role for ARID3a and miR125b on the upregulation of pluripotency markers, we quantified and compared their expression in pMIE-125b-or pSh-Arid3a-transduced 70Z/3 cells. All four pluripotency markers were found to be overexpressed in cells whose expression of Arid3a had been repressed using either microRNA (pMIE-125b) or by small interfering RNA (pSh-Arid3a) (Supplementary Figure S5) . In parallel, we knocked down miR-125b in human REH cells and observed a good correlation between the increased expression of ARID3a and the reduction of OCT4, SOX2, KLF4 and NANOG transcripts (Supplementary Figure S5) . Thus, our data show that, in B-ALL, miR-125b upregulation is associated with an ARID3a downregulation and an increase in the expression of pluripotency-associated markers.
miR-125b overexpression does not block differentiation of B-cell progenitors in vitro
The second distinct event occurring in B-ALL transformation is the blockage of differentiation at the pre-B-cell stage, therefore we tested whether overexpression of miR-125b and repression of Arid3a altered B-cell differentiation. Murine wild-type pre-BI cells were transduced with either retroviral constructs: pMIE, pMIE-miR-125b, pMIE-miR-125b-mut, pSh-Neg or pSh-Arid3a; or with a vector expressing PAX5-ELN (pMIE-PAX5-ELN) as a positive control. PAX5-ELN is a chimeric gene isolated from B-ALL patients in our laboratory by Bousquet et al., 18 and is associated with a blockage in differentiation at the pre-B-cell stage. Transduced cells were co-cultured for 6 days with OP9 cells in the presence or absence of IL-7 (IL-7 starvation assay 19 ). Usually IL-7 withdrawal causes pre-BI cells to stop proliferating, start differentiating and eventually undergo apoptosis in vitro. 19 We used expression levels of BP1 and surface Igk to determine which B-cell progenitors were present under each condition at day 6 of culture. BP1 is a 140-kDa type II transmembrane protein with aminopeptidase A activity and is expressed from the early pro-B to the late pre-B stages, with expression diminishing after that. In contrast, surface Igk is detected only during the later stages of differentiation. Cells were stained and EGFP-positive living cells were analyzed by flow cytometry. In the presence of IL-7, 60% of B-cells expressed BP1 and only 3% expressed Igk (Figure 7, Supplementary Figure S6) , reflecting the persistence of B-cell progenitors at the pre-BI stage (BP1 þ /Igk À ). In the presence of IL-7, BP1 and Igk expression levels were comparable between non-transduced cells and cells transduced by pMIE, pMIE-miR-125b, pMIE-miR-125b-MUT and pMIE-PAX5-ELN (Figure 7, Supplementary Figure S6) . However, upon IL-7 withdrawal around 20% of cells expressed BP1 and B35% of this population were expressing Igk (BP1 À /Igk þ ), indicating that differentiation of the B-cell progenitors had taken place. In contrast, 45% of control cells transduced with the positive control pMIE-PAX5-ELN þ expressed BP1 in the absence of IL-7. This reflects the ability of the chimeric PAX5-ELN protein to block B-cell differentiation (Po0.01). Loss of BP1 and acquaintance of Igk expression were comparable between non-transduced, control and miR-125b-expressing cells (Figure 7 , Supplementary  Figure S6 ), suggesting that this microRNA had no significant impact on normal B-cell differentiation. However, pre-BI cells in which Arid3a was knocked down were blocked at the pre-BII stage of differentiation upon IL-7 deprivation, as they lacked the BP1 surface marker and did not express Igk (Figure 7, Supplementary  Figure S6) .
These results show that repression of Arid3a can block B-cell differentiation in vitro and suggests a mechanism by which miR-125b overexpression in B-ALL cells could cause a reduction in Arid3a levels and subsequent blockage of B-cell differentiation, thus contributing toward B-ALL transformation.
DISCUSSION
Recent reports of cases of B-ALL presenting with an insertion of miR-125b-1 into the IGH locus [8] [9] [10] prompted us to analyze the effect of miR-125b-1 overexpression on the development of B-cell progenitors. Here we have shown that miR-125b overexpression could contribute to leukemogenesis by conferring a proliferative advantage and anti-apoptotic capacity that is independent of p53 and directly targets ARID3a, a transcriptional activator of the heavy-chain immunoglobulin gene. 20 B-ALL transformation requires a blockage in differentiation as well as a clonal expansion of malignant cells with a significant growth advantage. Using the pre-B-cell differentiation model developed by A Rolink, 19 we found that enforced expression of miR-125b in murine pre-BI cells did not have a significant effect on B-cell differentiation. However, in our experiments only a moderate expression (fivefold over mean) of miR-125b occurred in pre-BI cells and led to a moderate repression of Arid3a. We suppose that this repression was not strong enough to induce the blockage in B-cell differentiation as pre-BI cells with a total repression of Arid3a (pSh-Arid3a-transduced pre-BI cells) did not acquire Igk, a marker for the late stages of B-cell differentiation. In support of this, it has previously been shown that B-ALL patients with the t(11;14)(q24;q32) translocation have a 30-to 600-fold higher expression of miR-125b compared with B-ALL cases without this translocation. 9 Here, we have shown that miR-125b overexpression leads not only to higher proliferation but also to remarkable inhibition of apoptosis. This was the case in wild-type progenitor B-cells as well as in murine and human pre-B-cell lines. A recent publication on miR-125b-2 in ETV6/RUNX1 B-ALL showed a survival advantage conferred by overexpression of miR-125b. 7 These findings are in line with our results; however, our report is the first to examine the effect of miR-125b in a wild-type pre-B-cell model, which is much Figure 7 . Total repression of Arid3a blocks in vitro differentiation of murine B-cell progenitors. Wild-type pre-BI cells, pMIE, pMIE-miR125b-, pMIE-miR-125b-mut-, pMIE-PAX-ELN-, pSh-Neg-and pSh-Arid3a-infected pre-BI cells were co-cultured with OP9 stroma cells in the presence or absence of IL-7 then stained at day 6 of culture using anti-BP1 and anti-Igk antibodies to differentiate B-cell progenitors
Histogram represents the percentage of each cell type. Data are taken from n ¼ 3 independent experiments at day 6 of culture and are presented as means ± s.d.
miR-125b targets ARID3a in B-ALLcloser to in vivo conditions as wild-type pre-B-cells are nonmodified, non-transformed cells and are directly isolated from the bone marrow of healthy mice. Furthermore, the pre-B-cell model is a dynamic system that allows us to test the effects of this microRNA on B-cell growth. Interestingly, the observed effects regarding proliferation and apoptosis were more pronounced in wild-type pre-BI cells compared with leukemic cell lines, which underscores the value of this model.
In this study, we also tested whether the observed antiapoptotic effect of miR-125b was because of direct targeting of the pro-apoptotic proteins p53 or BAK1. In fact, both of these proteins are predicted targets of miR-125b from bioinformatics-based prediction tools, and a recent publication further suggests that the whole p53 network is a conserved target of miR-125b. 21 In this study, seven genes were identified, including upstream regulators of p53 and downstream effectors such as BAK1, that all contain putative binding sites for miR-125b. 21 Although these are not all conserved across species, each vertebrate species has a binding site for miR-125b in at least one of these genes, underlining the importance of the p53 network as a target of miR-125b. 21 In addition, p53 and BAK1 have already been experimentally proven as targets of miR-125b in humans. 4, 11 However, when we tested whether p53 and BAK1 expression levels were affected by miR125b expression in progenitor B-cells, we found no change in their protein levels. Although p53 is not a direct target of miR-125b in mice, it can be indirectly affected in its expression by upstream regulators as shown in mouse fibroblasts. 11 However, in a pre-Bcell context, we showed here that p53 and BAK1 are not targeted by miR-125b, hence the anti-apoptotic effects we observed are probably related to other mechanisms. Our results are reinforced by data by Gefen et al.
7 on miR-125b-2 in ETV6/RUNX1 leukemia, where the conferred survival advantage is also p53-independent.
MicroRNAs are highly versatile molecules. This is partially explained by the fact that a single microRNA can have hundreds of targets, which are differentially expressed depending on the cell type. 22 Thus, miR-125b has been implicated in mechanisms as diverse as metabolism, 23 the innate immune response, 24 neuronal differentiation, 25, 11 hematopoiesis 26, 27 and cancer. 5, 9, 10, 28 In cancer, miR-125b is reported to have different effects in different tumors. For example, tumor suppressor activity in breast cancer 29 and ovarian carcinoma, 30 as well as oncogenic properties in pancreatic cancer, 31 prostate cancer, 4 myelodysplastic syndrome and acute myeloid leukemia, 5 megakaryoblastic leukemia 32 and B-ALL, 7, 33 have all been related to this microRNA. miR-125b can even have opposite effects on the same process as it augments proliferation in prostate cancer cells 4 but inhibits cell cycling in hepatocellular carcinoma, 16 suggesting that miR-125b might act as an oncogene and/or a tumor suppressor, depending on the cellular context. To identify pertinent miR-125b targets in a pre-Bcell context, we performed gene expression profiling of a leukemic B-cell line using this microRNA. We showed that the ARID3a/Bright gene is a direct target of miR-125b at both mRNA and protein levels, in both murine B-cell progenitor cells as well as in B-ALL cell lines. Moreover, in the same cellular context this repression mimics the proliferative and anti-apoptotic effects induced by miR-125b.
Our study emphasizes the fact that miR-125b can act as an oncogene in progenitor B-cells by targeting ARID3a/Bright, a transcription factor implicated in the regulation of expression of the immunoglobulin heavy chain 20 and in cellular plasticity. 15, 16 Interestingly, in the mouse Arid3a/Bright, expression is tightly regulated and is restricted to B-cells but it is not expressed in all human B-lymphocyte subpopulations. Indeed, in human cells Bright is expressed in early B-lymphocyte precursors (pro-B and pre-B cells) and in germinal center cells, 34, 35 places where miR125b overexpression has already been described. 36 Finally, in B-ALL patients with the t(11;14)(q24;q32) translocation, we have shown that the expression of ARID3a is dramatically repressed. Thus, in B-ALL overexpressing miR-125b several lines of evidence suggest that this microRNA targets ARID3a/Bright and maintains the progenitor characteristics of pre-BI cells by controlling the expression of pluripotency-associated factors. Furthermore, the repression of ARID3a could lead to inhibition of differentiation of pre-BI cells by preventing the transcription of immunoglobulin heavy-chain genes. A recent study reported that in pediatric ALL cases, overexpression of miR-125b is associated with resistance to vincristine, particularly in patients carrying the TEL-AML1 translocation. 37 Therefore, it would be interesting to investigate the mechanisms of cellular resistance to chemotherapy in malignancies with an up-regulation of miR-125b.
